Navigation Links
David H. Koch donates $10 million to Mount Sinai's Jaffe Food Allergy Institute
Date:4/10/2012

David H. Koch, Executive Vice President of Koch Industries, has committed $10 million to the Jaffe Food Allergy Institute at The Mount Sinai Medical Center. The gift is one of the largest in the Institute's history and will create the David H. and Julia Koch Research Program in Food Allergy Therapeutics. The program will serve as a hub for drug discovery and vaccine development related to food allergy, and build upon the promising work already underway at the Institute. The donation will also be used to further the Institute's recruitment of leading researchers dedicated to the discovery of new food allergy therapeutics.

Nearly 15 million Americans have food allergies, including approximately 6 million children, according the The Food Allergy & Anaphylaxis Network. A 2010 study led by Scott Sicherer, MD, Chief of the Division on Allergy and Immunology in the Department of Pediatrics and a clinical researcher at the Jaffe Food Allergy Institute found the rates of childhood peanut allergies, one of the most common and most dangerous food allergies, more than tripled between 1997 and 2008.

Because the preventive shots used for allergies such as pollen or bee stings cause severe unwanted side effects when used for food allergies, scientists at the Institute are conducting cutting-edge research investigating using small fragments of the three main allergenic proteins present in peanuts to create a "safe shot." If successful in preventing peanut allergy, the theory could be applied to vaccines for all food allergies. Mr. Koch's donation will support these studies as well as efforts to identify new targets and biomarkers for food allergy.

"This generous gift will strengthen Mount Sinai's position as a global leader in food allergy therapeutics," said Hugh Sampson, MD, Director of the Jaffe Food Allergy Institute and an internationally recognized allergist and investigator of food allergy. "Right now, the only recourse for patients who have food allergies is to avoid those foods. This program has the potential to deliver the first therapies and cures for food allergies."

The research conducted by the program will be especially significant for children's health, according to Kenneth L. Davis, President and CEO of The Mount Sinai Medical Center. "Breakthrough therapeutics such as these will change the face of children's health," he said. "Mr. Koch's visionary philanthropy brings us one step closer to that goal."

Mr. Koch is a major advocate for medical research, and has long supported research into food allergies. "This is an exhilarating time for science and medicine in food allergy, and Dr. Sampson and his team are the best at what they do, but the most exciting discoveries are yet to come," said Mr. Koch. "My hope is that in the not-too-distant future, children who suffer from life-threatening food allergies will have their lives transformed from the therapies that originated here."

The Jaffe Food Allergy Institute was established in 1997 with the mission to expand and improve basic science and clinical research, comprehensive patient care, and educational efforts in the field of food allergy. Recent findings and ongoing studies include:

  • The group recently published a study showing that introducing food products containing baked milk into the diets of children who have milk allergy helps the majority of them outgrow their milk allergy more quickly;

  • In the first-ever study to assess the social impact of food allergies in children, researchers led by Dr. Scott Sicherer, found that approximately 35 percent of children over the age of five with food allergies, experience bullying, teasing, or harassment as a result of their allergies;

  • A team led by Dr. Sampson is currently conducting a clinical trial investigating the effectiveness of oral immunotherapy combined with the anti-IgE medication omalizumab in the treatment of cow's milk allergy;

  • A team of investigators led by Julie Wang, MD, Assistant Professor of Allergy and Immunology and Xiu-Min Li, MD, Professor of Pediatrics, is currently conducting a clinical trial investigating the effectiveness of Chinese herbs as a treatment for peanut, tree nuts, sesame, fish, or shellfish allergies;

  • A team led by Dr. Sampson is investigating other novel forms of immunotherapy including peptide-based vaccines and engineered recombinant protein-based vaccines.

By combining a world-class clinical research program with an equally strong laboratory-based one, the Jaffe Food Allergy Institute is uniquely able to move ideas and investigations between the laboratory bench and the patient's bedside in order to approach these disorders as efficiently and creatively as possible. The major goal is to devise more definitive, hopefully curative, therapies for food allergic disease.


'/>"/>

Contact: Jeanne Bernard
Jeanne.Bernard@mountsinai.org
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Legendary Hollywood directors and renowned researchers awarded 2011 Dan David Prizes
2. David Cheresh receives top award for cancer metastasis research
3. Chopra Center Co-Founder and Mind-body Healing Pioneer David Simon, M.D. Diagnosed with Brain Tumor
4. Phoenix DUI Lawyer, David Michael Cantor, Speaks to The Young Adult Forum
5. Complicated Surgeries Carry Greater Risks, Possible Need for New York Medical Malpractice Attorneys According To David Perecman
6. New York Construction Accident Attorney, David Perecman, Supports MTA Night Work
7. David Hofer Named President of International Bancard Corporation
8. New York Personal Injury Lawyer, David Perecman, says New Playground is No Place for Kids
9. Chinatown Fire is Caused by Negligence, New York Personal Injury Attorney, David Perecman, Believes
10. David Perecman Comments On Bus Driver Assaulting Supervisor In New York
11. Dr. David Blyweiss Announces New IBS Relief Protocol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... August 22, 2017 , ... John Stewart joins Privis ... Member for t4 Leadership Development & Consulting. He has spent his career focusing ... physician leadership development, servant leadership, data driven process improvement, and supportive technology. These ...
(Date:8/21/2017)... (PRWEB) , ... August 22, 2017 , ... ... but not without risk to health and safety. By learning and implementing best ... eliminated. , In this webinar, attendees will gain a better understanding of ...
(Date:8/21/2017)... ... ... Five chefs from local senior assisted living homes will serve Mediterranean-inspired gourmet ... be able to vote for their favorite Chef among the following: , GREECE, Chef ... Cheese Sauce & Garlic Pita Crisp, Greek Mountain Ice Tea , ITALY, Chef Gabriel ...
(Date:8/21/2017)... ... , ... The American Hospital Association (AHA) has elected Claire Zangerle, Chief Nurse ... Board of Trustees for a three-year term beginning January 1, 2018. , The ... that are committed to the improvement of health in their communities. Founded in 1898, ...
(Date:8/20/2017)... ... August 20, 2017 , ... HIPAA Solutions, LC ... has assisted multiple clients in successfully passing audits such as Office of Civil ... (AICPA SOC Level 2), and State Data Use Agreement Audits. , HIPAA ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... Mich. , Aug. 7, 2017 Diplomat Pharmacy, ... of Joel Saban as president, effective Aug. 7, ... Urick has decided to pursue other interests and will ... "During his tenure, Paul has served us in multiple leadership ... Specialty Pharmacy in Jun. 2015 and has provided decisive, strategic ...
(Date:8/7/2017)... , Aug. 7, 2017  Endo International plc ... reached agreements to resolve virtually all known U.S. mesh ... discussions to resolve the known remaining U.S. claims at ... payments beginning in the fourth quarter of 2017 and ... of its second quarter 2017 results, the Company intends ...
(Date:8/4/2017)... CINCINNATI , Aug. 3, 2017  Agragen, ... science company active in the biopharmaceutical, nutraceutical, and ... its development of its lead drug candidates, AGR131.  ... a proinflammatory cytokine from the blood of patients ... psoriasis, and inflammatory bowel disease. ...
Breaking Medicine Technology: